Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CF33-hNIS + modified FOLFOX
- Development stage
- Unknown
- Lead developer
- Imugene
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Intratumoral
01
Overview
**CF33-hNIS + modified FOLFOX** is an investigational combination regimen involving an *oncolytic virus*, CF33-hNIS (also known as VAXINIA), and a chemically modified version of the standard chemotherapy regimen FOLFOX. CF33-hNIS is a genetically engineered chimeric poxvirus designed to selectively infect, replicate within, and lyse cancer cells, simultaneously expressing the human sodium-iodide symporter (hNIS) to enable imaging, tracking, and potential radiotherapeutic add-ons[3][1]. The mechanism of CF33-hNIS involves direct oncolysis as well as immune-mediated antitumor activity via enhanced antigen presentation and recruitment of immune effector cells[1][3]. Modified FOLFOX is a variation of the classic FOLFOX regimen, containing oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, which acts as a cytotoxic chemotherapy backbone and can enhance immunogenic cell death, synergizing with virotherapy. This combination is being evaluated mainly in clinical trials for the treatment of advanced solid tumors, such as metastatic gastrointestinal cancers. CF33-hNIS was co-developed by City of Hope and Imugene[1][3].
- Brand names
- VAXINIA
- Other names
- CF33-hNISCF-33-hNISCF 33-hNISmodified FOLFOX
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on CF33-hNIS + modified FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CF33-hNIS + modified FOLFOX.